Bristol Myers Squibb (BMS) yesterday became the 12th drug manufacturer to impose restrictions on 340B pricing when hospitals and grantee covered entities contract with pharmacies to dispense drugs to patients.
According to late-day email messages from BMS to 340B customers and a one-page fact sheet, beginning March 1 the company will let hospitals buy its covered outpatient drugs—with three exceptions—at the 340B price only through the hospital’s in-house pharmacy or only through just one contract pharmacy.
Bristol Myers Squibb (BMS) yesterday became the 12
th drug manufacturer to impose restrictions on 340B pricing when hospitals and grantee covered entities contract with pharmacies to dispense drugs to patients.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
